4-(4-fluoro-benzyl)-1-methyl-piperidin-4-ol | 2804-65-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-fluoro-benzyl)-1-methyl-piperidin-4-ol
• 英文别名: 4-(4-Fluor-benzyl)-1-methyl-piperidin-4-ol；4-[(4-Fluorophenyl)methyl]-1-methylpiperidin-4-ol
• CAS: 2804-65-1
• 化学式: C₁₃H₁₈FNO
• 分子量: 223.29
• InChiKey: BMKULQXIMPKDDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-fluoro-benzyl)-1-methyl-piperidin-4-ol 、 丙酸酐 在 吡啶 作用下， 生成 4-(4-fluoro-benzyl)-1-methyl-4-propionyloxy-piperidine
  参考文献：
  名称：

  Harper; Simmonds, Journal of medicinal and pharmaceutical chemistry, 1959, vol. 1, p. 181,183, 184

  摘要：

  DOI：
• 作为产物：
  描述：

  N-甲基-4-哌啶酮 、 4-Fluorophenylmagnesium chloride 在 乙醚 作用下， 生成 4-(4-fluoro-benzyl)-1-methyl-piperidin-4-ol
  参考文献：
  名称：

  Harper; Simmonds, Journal of medicinal and pharmaceutical chemistry, 1959, vol. 1, p. 181,183, 184

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
  申请人：ANDREWS STEVEN W

  公开号：WO2018071454A1

  公开（公告）日：2018-04-19

  Provided herein are compounds of the Formula I: (I) or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了Formula I的化合物：(I)或其药用可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D、E、Ra、Rb、n和m的含义如规范中所述，它们是RET激酶的抑制剂，并且在治疗和预防可以用RET激酶抑制剂治疗的疾病中非常有用，包括与RET相关的疾病和紊乱。
• Piperidine derivative having nmda receptor antagonistic activity
  申请人：Yano Toshisada

  公开号：US20070082927A1

  公开（公告）日：2007-04-12

  A piperidine derivative of the formula (I) is found to bind specifically with the NR1/NR2B receptor and usable as an analgesic (pain treatment drug). wherein X is OH or lower alkylsulfonyloxy; Ar is optionally substituted aryl or optionally substituted heteroaryl; n is an integer of 1 to 4; m is an integer of 0 to 1; R 1 is hydrogen; R 2 is OH or R 1 and R 2 taken together may form a single bond; excluding that 1) n is 2; m is 0; R 1 and R 2 taken together may form a single bond; and Ar is optionally substituted phenyl and 2) n is 3; m is 0; R 1 and R 2 taken together may form a single bond; and Ar is phenyl.

  公式（I）的哌啶衍生物被发现能够与NR1/NR2B受体特异性结合，并可用作镇痛剂（治疗疼痛的药物）。其中X为OH或较低的烷基磺酰氧基；Ar为可选的取代芳基或可选的取代杂环芳基；n为1至4的整数；m为0至1的整数；R1为氢；R2为OH或R1和R2结合可形成单键；不包括1）n为2；m为0；R1和R2结合可形成单键；Ar为可选的取代苯基和2）n为3；m为0；R1和R2结合可形成单键；Ar为苯基。
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array Biopharma Inc.

  公开号：US20200030311A1

  公开（公告）日：2020-01-30

  Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X 1 , X 2 , X 3 , X 4 , Ring D, E, R a , R b , n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
• US7786140B2
  申请人：——

  公开号：US7786140B2

  公开（公告）日：2010-08-31